参考文献/References:
[1] 胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志,2019,34(3):209-220.
[2] Golia E,Limongelli G,Natale F,et al. Inflammation and cardiovascular disease:from pathogenesis to therapeutic target[J]. Curr Atheroscler Rep,2014,16(9):435.
[3] Zhuang X,Wu B,Li J,et al. The emerging role of interleukin-37 in cardiovascular diseases[J]. Immun Inflamm Dis,2017,5(3):373-379.
[4] Dunn E,Sims JE,Nicklin MJ,et al. Annotating genes with potential roles in the immune system:six new members of the IL-1 family[J]. Trends Immunol,2001,22(10):533-536.
[5] Lunding L,Webering S,Vock C,et al. IL-37 requires IL-18Rα and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice[J]. Allergy,2015,70(4):366-373.
[6] Taylor SL,Renshaw BR,Garka KE,et al. Genomic organization of the interleukin-1 locus[J]. Genomics,2002,79(5):726-733.
[7] Kumar S,Hanning CR,Brigham-Burke MR,et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production[J]. Cytokine,2002,18(2):61-71.
[8] Nold MF,Nold-Petry CA,Zepp JA,et al. IL-37 is a fundamental inhibitor of innate immunity[J]. Nat Immunol,2010,11(11):1014-1022.
[9] Cavalli G,DInarello CA. Suppression of inflammation and acquired immunity by IL-37[J]. Immunol Rev,2018,281(1):179-190.
[10] Rafieian-Kopaei M,Setorki M,Doudi M,et al. Atherosclerosis:process,indicators,risk factors and new hopes[J]. Int J Prev Med,2014,5(8):927-946.
[11] Xie Y,Li Y,Cai X,et al. Interleukin-37 suppresses ICAM-1 expression in parallel with NF-κB down-regulation following TLR2 activation of human coronary artery endothelial cells[J]. Int Immunopharmacol,2016,38:26-30.
[12] Hong YJ,Jeong MH,Ahn Y,et al. Relationship between peripheral monocytosis and nonrecovery of left ventricular function in patients with left ventricular dysfunction complicated with acute myocardial infarction[J]. Circ J,2007,71(8):1219-1224.
[13] Wu BW,Zeng QT,Meng K,et al. The potential role of IL-37 in atherosclerosis[J]. Pharmazie,2013,68(11):857-860.
[14] Zhou P,Li Q,Su S,et al. Interleukin 37 Suppresses M1 Macrophage Polarization Through Inhibition of the Notch1 and Nuclear Factor Kappa B Pathways[J]. Front Cell Dev Biol,2020,8:56.
[15] McCurdy S,Baumer Y,Toulmin E,et al. Macrophage-specific expression of il-37 in hyperlipidemic mice attenuates atherosclerosis[J]. J Immunol,2017,199(10):3604-3613.
[16] Ji Q,Meng K,Yu K,et al. Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice[J]. Sci Rep,2017,7(1):3310.
[17] Yu K,Min X,Lin Y,et al. Increased IL-37 concentrations in patients with arterial calcification[J]. Clin Chim Acta,2016,461:19-24.
[18] Liu J,Lin J,He S,et al. Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability[J]. Cell Physiol Biochem,2018,45(3):1034-1050.
[19] Huang J,Hou FL,Zhang AY,et al. Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis[J]. Genet Mol Res,2016,15(2):gmr7616.
[20] Chai M,Ji Q,Zhang H,et al. The protective effect of interleukin-37 on vascular calcification and atherosclerosis in apolipoprotein e-deficient mice with diabetes[J]. J Interferon Cytokine Res,2015,35(7):530-539.
[21] Fang L,Moore XL,Dart AM,et al. Systemic inflammatory response following acute myocardial infarction[J]. J Geriatr Cardiol,2015,12(3):305-312.
[22] Ji Q,Zeng Q,Huang Y,et al. Elevated plasma IL-37,IL-18,and IL-18BP concentrations in patients with acute coronary syndrome[J]. Mediators Inflamm,2014,2014:165742.
[23] Li J,Zhang W,Yao H,et al. Therapeutic effects of interleukin-37 and induced cardiosphere on treating myocardial ischemia-reperfusion injury[J]. Int Immunopharmacol,2020,88:106719.
[24] Wu B,Meng K,Ji Q,et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice[J]. Clin Exp Immunol,2014,176(3):438-451.
[25] Yang T,Fang F,Chen Y,et al. Elevated plasma interleukin-37 playing an important role in acute coronary syndrome through suppression of ROCK activation[J]. Oncotarget,2017,8(6):9686-9695.
[26] Mao X,Zhu R,Zhang F,et al. IL-37 plays a beneficial role in patients with acute coronary syndrome[J]. Mediators Inflamm,2019,2019:9515346.
[27] Xu D,Wang A,Jiang F,et al. Effects of interleukin-37 on cardiac function after myocardial infarction in mice[J]. Int J Clin Exp Pathol,2015,8(5):5247-5251.
[28] Zhu R,Sun H,Yu K,et al. Interleukin-37 and dendritic cells treated with interleukin-37 plus troponin I ameliorate cardiac remodeling after myocardial infarction[J]. J Am Heart Assoc,2016,5(12):e004406.
[29] Chugh SS,Havmoeller R,Narayanan K,et al. Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study[J]. Circulation,2014,129(8):837-847.
[30] Aviles RJ,Martin DO,Apperson-Hansen C,et al. Inflammation as a risk factor for atrial fibrillation[J]. Circulation,2003,108(24):3006-3010.
[31] Li W,Li S,Li X,et al. Interleukin-37 elevation in patients with atrial fibrillation[J]. Clin Cardiol,2017,40(2):66-72.
[32] Shirazi LF,Bissett J,Romeo F,et al. Role of inflammation in heart failure[J]. Curr Atheroscler Rep,2017,19(6):27.
[33] Pasqui AL,di Renzo M,Bova G,et al. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes[J]. Clin Exp Med,2006,6(1):38-44.
[34] Kang SH,Park JJ,Choi DJ,et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF[J]. Heart,2015,101(23):1881-1888.
[35] Shou X,Lin J,Xie C,et al. Plasma IL-37 elevated in patients with chronic heart failure and predicted major adverse cardiac events:a 1-year follow-up study[J]. Dis Markers,2017,2017:9134079.
[36] Sagar S,Liu PP,Cooper LT Jr. Myocarditis[J]. Lancet,2012,379(9817):738-747.
[37] An B,Liu X,Li G,et al. Interleukin-37 ameliorates coxsackievirus B3-induced viral myocarditis by modulating the Th17/regulatory T cell immune response[J]. J Cardiovasc Pharmacol,2017,69(5):305-313.
[38] Guzik TJ,Touyz RM. Oxidative stress,inflammation,and vascular aging in hypertension[J]. Hypertension,2017,70(4):660-667.
[39] Ye J,Wang Y,Wang Z,et al. Circulating IL-37 levels are elevated in patients with hypertension[J]. Exp Ther Med,2021,21(6):558.
相似文献/References:
[1]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(2):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[2]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(2):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[3]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[4]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(2):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[5]顾佳仪 刘正霞 鲁翔.白介素-1β在冠心病中的研究进展[J].心血管病学进展,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
Gu Jiayi,Liu Zhengxia,Lu Xiang.Interleukin-1 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
[6]王辉 蒋永兴 田野.下肢动脉硬化闭塞症：炎症机制与抗炎治疗的研究进展[J].心血管病学进展,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
WANG HuiJIANG YongxingTIAN Ye.Peripheral Arterial DiseaseA Research Progress Review of Inflammatory Mechanism and Anti-inflammatory Therapy[J].Advances in Cardiovascular Diseases,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
[7]严宁,杨春霞,马娟,等.β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J].心血管病学进展,2020,(3):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
YAN Ning,YANG Chunxia,MA Juan,et al.Effects of -sitosterolon Myocardial Ischemia-reperfusion Injury and ERK1/2 Signaling Pathway in Rats[J].Advances in Cardiovascular Diseases,2020,(2):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
[8]韩月 朱莉 宋桂仙.白介素-12家族在冠状动脉粥样硬化中的研究进展[J].心血管病学进展,2020,(5):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
HAN Yue,ZHU Li,SONG Guixian.Interleukin-12 Family in Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(2):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
[9]汪汉,刘汉雄,蔡琳.2019冠状病毒病的心血管表现[J].心血管病学进展,2020,(11):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
WANG Han,LIU Hanxiong,CAI Lin.Cardiovascular Profiles in Corona V irus Disease 2019[J].Advances in Cardiovascular Diseases,2020,(2):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[10]张颖怡 刘金波 刘欢 赵娜 赵红薇 王宏宇.全身动脉粥样硬化斑块与脑梗死的关系：北京血管病变评价研究结果[J].心血管病学进展,2021,(3):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
ZHANG YingyiLIU J inboLIU HuanZHAO NaZHAO HongweiWANG Hongyu.The Relationship Between Systematic Atherosclerotic Plaques and Cerebral Infarction:Results from Beijing Vascular Disease Evaluation Study[J].Advances in Cardiovascular Diseases,2021,(2):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]